ASH 2023 | Ibrutinib in previously untreated high-risk smoldering MCL: insights from a Phase II trial
Charles Gaulin, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II clinical trial (NCT03282396) investigating the safety and efficacy of ibrutinib in patients with previously untreated high-risk smoldering mantle cell lymphoma (MCL). All patients achieved a response, with around half reaching a complete response (CR). Of the eight patients who discontinued treatment, seven did so due to treatment-related toxicities. Dr Gaulin also discusses the next steps in this patient population, mentioning some other studies investigating BTK inhibitors in these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
